Prophylaxis Against Covid-19: Analysis Of The Supply of Hydroxychloroquine and Ivermectin and Covid-19 Cases and Deaths

Maiara Cristina De Cesaro; Andressa de Souza; Fernanda Rabaioli da Silva; Douglas Nunes Stahnke; Rafael Fernandes Zanin; Liciane Fernandes Medeiros

doi:10.18316/sdh.v11i3.10214

Autores

Maiara Cristina De Cesaro Programa de Pós-Graduação em Saúde e Desenvolvimento Humano, Universidade La Salle, Canoas-RS/Brasil. http://orcid.org/0000-0002-6256-0535
Andressa de Souza Docente do Programa de Pós-Graduação em Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre-RS, Brasil http://orcid.org/0000-0002-6608-4695
Fernanda Rabaioli da Silva Docente do Programa de Pós-Graduação em Saúde e Desenvolvimento Humano, Universidade La Salle, Canoas-RS/Brasil. http://orcid.org/0000-0001-9130-7435
Douglas Nunes Stahnke Doutorando pelo Programa de Pós-Graduação em Saúde Coletiva, Universidade do Vale do Rio dos Sinos, São Leopoldo-RS, Brasil. http://orcid.org/0000-0002-6871-4355
Rafael Fernandes Zanin Docente do Programa de Pós-Graduação em Saúde e Desenvolvimento Humano, Universidade La Salle, Canoas-RS/Brasil. https://orcid.org/0000-0003-3146-0221
Liciane Fernandes Medeiros Docente do Programa de Pós-Graduação em Saúde e Desenvolvimento Humano, Universidade La Salle, Canoas-RS/Brasil. http://orcid.org/0000-0002-6842-7241

DOI:

https://doi.org/10.18316/sdh.v11i3.10214

Palavras-chave:

Hydroxychloroquine, Ivermectine, zithromycin, Mortality

Resumo

Introduction: The prophylaxis of the COVID-19 diseases remains questionable, regarding ivermectin, hydroxychloroquine and azithromycin action. Objective: This is an interrupted time series ecological study where a temporal analysis of the consumption of medications in the pre-pandemic and pandemic periods in the São Lourenço do Oeste (SLO) city was performed. Material and methods: Data were collected monthly from January 2018 to March 2021 directly from pharmacies/drug stores for medications, and from April 2020 to March 2021 for COVID-19. The temporal analysis was performed using the Prain Winsten test. Associations between variables (drugs and COVID-19 data) were made by Spearman's correlation test. Results: The supply of ivermectin (coefficient, 7.71 p=0.005) and hydroxychloroquine increased (coefficient 26.84, p=0.021) in the pandemic; and azithromycin remained stable (p? 0.05). There was a positive correlation between new cases of COVID-19 and the supply of azithromycin, hydroxychloroquine and ivermectin (Spearman rho 0.857, 0.760 and 0.741 p<0.01, respectively) and a positive correlation between deaths with azithromycin (Spearman rho 0.690, p<0.01) and hydroxychloroquine (Spearman rho 0.617, p<0.05). Conclusions: According to our data, it is possible to infer that the increased supply of ivermectin, azithromycin or hydroxychloroquine was not able to reduce new cases or deaths by COVID-19, showing no effectiveness as prophylaxis of this disease.

Referências

Pan American Health Organization. Folha informativa sobre Covid-19. https://www.paho.org/pt/covid19; 2021 Accessed 23.11.2021.

Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Martinez JPD et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373 (949):1-17. DOI: https://doi.org/10.1136/bmj.n949.

RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 2021;397(10274):605-612. DOI: https://doi.org/10.1016/S0140-6736(21)00149-5.

Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine. 2021;33(100773):1-10. DOI: https://doi.org/10.1016/j.eclinm.2021.100773.

Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2021;28(7):1-156. DOI: https://doi.org/10.1002/14651858.CD015017.pub2.

Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. The Cochrane database of systematic reviews. 2021;12(2):1-92. https://doi.org/10.1002/14651858.CD013587.pub2.

Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(965)1-4. DOI: https://doi.org/10.1186/s13063-020-04813-1.

Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR et al. Eff ect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2020; 383(21):2030-2040. DOI: 10.1056/NEJMoa2022926.

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E et al. Eff ect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(14):1426-1435. DOI: 10.1001/jama.2021.3071.

Nexo. Quanto as farmacêuticas ganharam com o ‘kit covid’. 2021. Available in: https://www.nexojornal.com.br/expresso/2021/08/11/Quanto-as-farmac%C3%AAuticas-ganharam-com-o-%E2%80%98kitcovid%E2%80%99.

Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M et al. Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics. 2021;10(132):1-11. DOI: https://doi.org/10.3390/antibiotics10020132.

Sulis G, Batomen B, Kotwani A, Pai M, Gandra S. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. PLoS medicine. 2021;18(7):e1003682. DOI: https://doi.org/10.1371/journal.pmed.1003682.

Alvarez A, Cabia L, Trigo C, Bandrés AC, Bestué M. Prescription profi le in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain. European Journal of Hospital Pharmacy. 2022; 29(1)287-289. DOI: http://dx.doi.org/10.1136/ejhpharm-2020-002476.

Cattaneo D, Pasina L, Maggioni AP, Giacomelli A, Oreni L, Covizzi A et al. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020;37(12):925-933. DOI: https://doi.org/10.1007/s40266-020-00812-8.

Romano S, Galante H, Figueira D, Mendes Z, Rodrigues AT. Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies. Res Social Adm Pharm. 2021;17(1):1876-1881. DOI: https://doi.org/10.1016/j.sapharm.2020.05.024.

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New England Journal of Medicine. 2020; 383(6):517-525. DOI: https://doi.org/10.1056/NEJMoa2016638.

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020; 369:m1432. DOI: 10.1136/bmj.m1432.

Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC et al. A pragmatic randomized controlled trial reports lack of effi cacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020;11(5284):1-6. DOI: https://doi.org/10.1038/s41467-020-19056-6.

Ma X, Wang Y, Gao T, He Q, He Y, Yue R et al. Challenges and strategies to research ethics in conducting COVID-19 research. Journal of evidence-based medicine. 2020;13(2):173-177. DOI: 10.1111/jebm.12388.

Vossen M. HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers. 2020. Available in: https://clinicaltrials.gov/ct2/show/NCT04336748.

Yogendrakumar V, Dewar B, McGuinty M, Dowlatshahi D, Dyason C, Kwok ES et al. Many trials of hydroxychloroquine for SARS-CoV-2 were redundant and potentially unethical: an analysis of the NIH clinical trials registry. Journal of Clinical Epidemology. 2022;143(1):73-80. DOI: https://doi.org/10.1016/j.jclinepi.2021.11.011.

Patel NA, Desai SS, Grainger DW, Mehra MR. Usefulness of Ivermectin in COVID-19 Illness. 2020. Available in: https://www.isglobal.org/documents/10179/6022921/Patel+et+al.+2020+version+2.pdf/adf390e0-7099-4c70-91d0-e0f7a0b69e14.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020;178(104787):1-4. DOI: https://doi.org/10.1016/j.antiviral.2020.104787.

Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Effi cacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. (2020). Available in: https://assets.researchsquare.com/fi les/rs-100956/v1/fcebdebf-8ab6-4c83-9c8d-e532a9a68474.pdf?c=1647142987.

Grau S, Hernández S, Echeverría-Esnal D, Almendral A, Ferrer R, Limón E et al. Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics. 2021;10(943):1-12. DOI: https://doi.org/10.3390/antibiotics10080943.

Mustafa ZU, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN comprehensive clinical medicine. 2021;3(1):1691-1695. DOI: https://doi.org/10.1007/s42399-021-00966-5.

Malin JJ, Spinner CD, Janssens U, Welte T, Weber-Carstens S, Schälte G et al. Key summary of German national treatment guidance for hospitalized COVID-19 patients: Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). Infection. 2022;50(1):93-106. DOI: https://doi.org/10.1007/s15010-021-01645-2.